Results 111 to 120 of about 128,590 (274)

The Impact of Atopic Dermatitis on Sexual Function and Reproductive Desires in Women

open access: yesActa Dermato-Venereologica
Atopic dermatitis is a prevalent skin condition that affects up to 17% of adult population. It can lead to itching, pain, and other symptoms such as sleep disturbance, anxiety, and depression.
Juan-Angel Rodríguez-Pozo   +6 more
doaj   +1 more source

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). [PDF]

open access: yes, 2014
This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III).
Admani, S   +43 more
core   +1 more source

Genital Psoriasis: Shining Light on This Hidden Disease

open access: yesJEADV Clinical Practice, EarlyView.
Psoriasis occurring on skin of the genital and perigenital regions has specific diagnostic and treatment requirements due to the sensitivity and private nature of these areas. A multidisciplinary group of experts in the management of genital psoriasis, the Genital Psoriasis Wellness Consortium, convened to discuss the impact of genital psoriasis on ...
Jennifer Cather   +19 more
wiley   +1 more source

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis

open access: yesClinical and Translational Allergy, 2023
Lotte S. Spekhorst   +11 more
doaj   +1 more source

Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease [PDF]

open access: yes, 2007
Background/aim: Interleukin 31 (IL31), primarily expressed in activated lymphocytes, signals through a heterodimeric receptor complex consisting of the IL31 receptor alpha (IL31R\textgreeka) and the oncostatin M receptor (OSMR). The aim of this study was
Auernhammer, Christoph J.   +6 more
core   +2 more sources

Causal association between atopic dermatitis and Parkinson's disease: A bidirectional Mendelian randomization study

open access: yesBrain and Behavior
Background Atopic dermatitis is one of the most common skin disorders. Evidence has suggested an association between skin disorders, such as atopic dermatitis, and Parkinson's disease (PD).
Taofeng Zhou   +5 more
doaj   +1 more source

A Survey on Methotrexate Prescribing and Monitoring Practices in Ireland

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Methotrexate, originally an anti‐neoplastic agent, is now extensively used at lower doses in dermatology and rheumatology for chronic inflammatory conditions. While its safety is supported by routine blood monitoring, there remains variability in recommended monitoring frequency, folic acid supplementation, liver function testing ...
Ji Fung Yong   +7 more
wiley   +1 more source

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. [PDF]

open access: yes, 2019
BackgroundComparative, real-life and long-term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is limited.
Apfelbacher, CJ   +17 more
core  

Targeting JAK‐1 in Disseminated Cutaneous Lichen Planus

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT We report the case of a 63‐year‐old woman with an exuberant and recalcitrant clinical presentation of LP who had an excellent response to 200 mg/day abrocitinib, a JAK‐1 inhibitor, after failure to other commonly used therapies. The efficacy of JAK inhibitors in lichen planus is supported by small case series and isolated case reports. Further
F. Barbosa, L. Siems, D. Luz, A. Duarte
wiley   +1 more source

Optimising Vaccination Status in a Belgian Dermatological Immune‐Mediated Inflammatory Disease Population: An Education‐Based Pro‐Active Patient‐Centred Approach

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Patients with dermatological immune mediated inflammatory diseases (IMIDs) are increasingly treated with immunosuppressive and ‐modulating drugs. Some of these drugs increase the risk of acquiring infections and more complications can arise during an infection while treated with these agents.
Femke Lieten   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy